Triera Biosciences

Triera Biosciences Logo

 Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA

Guelph, ON – March 25, 2024, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. (“Triera”) has completed testing demonstrating that its C19HBA SARS-CoV-2 universal aptamer built on the proprietary high-binding affinity aptamer platform has shown a promising safety and toxicity Read more…